Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guerbet S.A. (GBT.PA)
Villepinte, FR
Guerbet SA is dedicated to the development and commercialization of a broad spectrum of contrast media, advanced delivery systems, medical devices, and related solutions for diagnostic imaging. Their extensive product lineup features iodinated contrast agents such as Optiray and Xenetix, both non-ionic monomeric; Telebrix Gastro, a meglumine ioxitalamate solution; and Conray, an iothalamate meglumine injection. They also offer Micropaque/Microtrast, an integrated diagnostic imaging solution. For MRI applications, the company provides gadoteric acid-based contrast agents like Dotarem (gadoterate meglumine) and Artirem. Complementing these are essential delivery systems and consumables, including prefilled syringes, injectors, and accessories designed for use in MRI, CT, and Cath Lab settings. Guerbet also delivers innovative digital health solutions such as Contrast&Care for injection management, Dose&Care for X-ray dose management, and icobrain, a cloud-based AI platform that quantifies disease-specific brain structures from MR and CT scans for acute and chronic neurological conditions. Additionally, they offer OptiProtect services. In the realm of interventional radiology, the company provides products like Lipiodol (ethyl esters of iodinated fatty acids of poppyseed oil), Vectorio (a mixing and injection system for conventional trans-arterial chemoembolization), Patent Blue V (a blue dye), Axessio (a peripheral micro guidewire), and microcatheters such as SeQure and DraKon. Furthermore, their offerings include Hydra Vision, a digital imaging system tailored for urological, gastroenterological, and gynecological treatment, planning, and diagnostic procedures, alongside various urology accessories and consumables. Established in 1926, Guerbet's headquarters are situated in Villepinte, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.10% | +9.97% | -7.76% | -19.91% | -39.07% | -25.17% | -46.90% | -37.06% | -65.59% | -82.47% | -10.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 1 | -1 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-7.6% Q4'25: -4.1% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-797.7% Q4'25: -588.9% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.4% Q4'25: +7.2% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+0.2% Q4'25: -26.8% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.2% Q4'25: -73.4% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q4'25: +4.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×7.04× Q4'25: 7.87× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 1999 actual |
Dec 2000 actual |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
185.74M
est.
|
197.03M
est.
|
213.74M
est.
|
228.84M
est.
|
228.71M
est.
|
247.49M
est: 248.89M (-0.6%)
|
269.48M
est: 274.24M (-1.7%)
|
289.41M
est: 293.36M (-1.3%)
|
305.55M
est: 310.69M (-1.7%)
|
320.78M
est: 327.37M (-2.0%)
|
335.48M
est: 340.69M (-1.5%)
|
352.58M
est: 362.35M (-2.7%)
|
377.83M
est: 383.57M (-1.5%)
|
404.25M
est: 406.25M (-0.5%)
|
390.60M
est: 395.70M (-1.3%)
|
409.51M
est: 415.29M (-1.4%)
|
489.91M
est: 473.45M (+3.5%)
|
776.47M
est: 777.30M (-0.1%)
|
808.63M
est: 807.10M (+0.2%)
|
794.61M
est: 789.60M (+0.6%)
|
816.91M
est: 816.93M (0.0%)
|
712.30M
est: 712.24M (+0.0%)
|
735.91M
est: 732.10M (+0.5%)
|
769.50M
est: 756.98M (+1.7%)
|
795.65M
est: 840.79M (-5.4%)
|
851.12M
est: 841.63M (+1.1%)
|
786.40M
est: 786.33M (+0.0%)
|
758.38M
754.75M – 762.00M
-3.6% YoY
|
794.72M
787.55M – 798.97M
+4.8% YoY
|
821.84M
821.84M – 821.84M
+3.4% YoY
|
| EBITDA |
-19.88M
est.
|
3.18M
est.
|
-1.19M
est.
|
6.75M
est.
|
22.93M
est.
|
45.05M
est: 11.64M (+286.9%)
|
51.72M
est: 24.24M (+113.4%)
|
43.10M
est: 56.72M (-24.0%)
|
51.33M
est: 41.96M (+22.3%)
|
56.47M
est: 49.89M (+13.2%)
|
47.91M
est: 47.95M (-0.1%)
|
27.88M
est: 45.47M (-38.7%)
|
42.61M
est: 27.78M (+53.4%)
|
51.89M
est: 35.36M (+46.7%)
|
51.41M
est: 44.11M (+16.5%)
|
62.49M
est: 51.61M (+21.1%)
|
85.48M
est: 69.40M (+23.2%)
|
103.15M
est: 149.99M (-31.2%)
|
116.75M
est: 91.35M (+27.8%)
|
104.85M
est: 95.80M (+9.4%)
|
111.64M
est: 109.05M (+2.4%)
|
79.21M
est: 106.14M (-25.4%)
|
85.09M
est: 109.65M (-22.4%)
|
32.29M
est: 112.62M (-71.3%)
|
102.59M
est: 80.59M (+27.3%)
|
96.71M
est: 80.57M (+20.0%)
|
62.21M
est: 75.37M (-17.5%)
|
72.69M
72.34M – 73.04M
-3.6% YoY
|
76.17M
75.49M – 76.58M
+4.8% YoY
|
78.77M
78.77M – 78.77M
+3.4% YoY
|
| EBIT |
-10.21M
est.
|
7.96M
est.
|
13.23M
est.
|
17.02M
est.
|
5.55M
est.
|
29.37M
est: 24.49M (+19.9%)
|
38.16M
est: 32.61M (+17.0%)
|
28.96M
est: 36.95M (-21.6%)
|
36.77M
est: 32.56M (+12.9%)
|
39.59M
est: 38.78M (+2.1%)
|
29.52M
est: 41.42M (-28.7%)
|
7.69M
est: 31.59M (-75.7%)
|
20.70M
est: 8.79M (+135.6%)
|
30.09M
est: 23.83M (+26.2%)
|
27.53M
est: 30.78M (-10.6%)
|
39.19M
est: 31.38M (+24.9%)
|
60.01M
est: 44.85M (+33.8%)
|
53.93M
est: 96.29M (-44.0%)
|
81.01M
est: 56.33M (+43.8%)
|
66.09M
est: 77.57M (-14.8%)
|
52.91M
est: 72.56M (-27.1%)
|
19.56M
est: 49.97M (-60.9%)
|
29.15M
est: 51.63M (-43.5%)
|
-28.51M
est: 53.03M (-153.8%)
|
41.44M
est: 16.48M (+151.5%)
|
35.42M
est: 16.47M (+115.0%)
|
1.36M
est: 15.41M (-91.2%)
|
14.86M
14.79M – 14.93M
-3.6% YoY
|
15.57M
15.43M – 15.66M
+4.8% YoY
|
16.11M
16.11M – 16.11M
+3.4% YoY
|
| Net Income |
-10.96M
est.
|
1.49M
est.
|
2.50M
est.
|
6.42M
est.
|
10.14M
est.
|
17.20M
est: 9.90M (+73.7%)
|
23.01M
est: 18.07M (+27.4%)
|
18.93M
est: 24.49M (-22.7%)
|
23.76M
est: 20.11M (+18.2%)
|
24.39M
est: 25.08M (-2.7%)
|
20.50M
est: 25.39M (-19.3%)
|
5.88M
est: 21.80M (-73.0%)
|
14.43M
est: 6.25M (+131.0%)
|
20.40M
est: 15.25M (+33.7%)
|
20.49M
est: 19.87M (+3.1%)
|
26.13M
est: 21.51M (+21.4%)
|
39.92M
est: 30.23M (+32.1%)
|
28.93M
est: 64.41M (-55.1%)
|
46.22M
est: 29.85M (+54.8%)
|
46.82M
est: 45.26M (+3.5%)
|
37.33M
est: 48.59M (-23.2%)
|
18.24M
est: 36.05M (-49.4%)
|
32.64M
est: 37.24M (-12.4%)
|
-41.12M
est: -42.73M (+3.8%)
|
23.87M
est: 32.76M (-27.2%)
|
16.08M
est: 28.67M (-43.9%)
|
-108.33M
est: -4.28M (-2,433.8%)
|
28.76M
28.54M – 28.99M
+772.7% YoY
|
24.30M
23.56M – 28.56M
-15.5% YoY
|
27.60M
25.11M – 34.50M
+13.6% YoY
|
| SGA |
71.02M
est.
|
70.65M
est.
|
74.42M
est.
|
75.80M
est.
|
61.27M
est.
|
15.94M
est: 80.20M (-80.1%)
|
15.89M
est: 92.99M (-82.9%)
|
20.33M
est: 91.69M (-77.8%)
|
—
est: 99.05M (-100.0%)
|
—
est: 100.84M (-100.0%)
|
—
est: 100.84M (-100.0%)
|
—
est: 108.49M (-100.0%)
|
—
est: 111.25M (-100.0%)
|
119.33M
est: 128.05M (-6.8%)
|
221.83M
est: 131.78M (+68.3%)
|
228.27M
est: 148.30M (+53.9%)
|
271.68M
est: 167.98M (+61.7%)
|
430.98M
est: 270.43M (+59.4%)
|
451.46M
est: 270.81M (+66.7%)
|
457.40M
est: 267.81M (+70.8%)
|
16.05M
est: 293.49M (-94.5%)
|
419.77M
est: 272.40M (+54.1%)
|
407.75M
est: 281.43M (+44.9%)
|
80.32M
est: 289.05M (-72.2%)
|
15.72M
est: 130.67M (-88.0%)
|
84.14M
est: 130.64M (-35.6%)
|
—
est: 122.21M (-100.0%)
|
117.86M
117.30M – 118.43M
-3.6% YoY
|
123.51M
122.40M – 124.17M
+4.8% YoY
|
127.73M
127.73M – 127.73M
+3.4% YoY
|
| EPS |
0.41
est.
|
0.21
est.
|
0.43
est.
|
0.62
est.
|
0.80
est.
|
1.48
est: 1.20 (+22.9%)
|
1.95
est: 1.86 (+5.0%)
|
1.59
est: 1.85 (-13.9%)
|
1.98
est: 1.89 (+4.7%)
|
2.03
est: 2.18 (-6.9%)
|
1.69
est: 1.58 (+6.9%)
|
0.48
est: 1.20 (-59.9%)
|
1.18
est: 1.15 (+2.9%)
|
1.67
est: 1.63 (+2.5%)
|
1.68
est: 1.48 (+13.2%)
|
2.14
est: 2.14 (+0.2%)
|
3.21
est: 2.67 (+20.5%)
|
2.33
est: 3.24 (-28.0%)
|
3.69
est: 3.70 (-0.4%)
|
3.72
est: 2.98 (+25.0%)
|
2.97
est: 2.83 (+5.0%)
|
1.45
est: 1.69 (-14.2%)
|
2.59
est: 2.38 (+9.0%)
|
-3.26
est: 0.92 (-455.1%)
|
1.89
est: 2.60 (-27.3%)
|
1.28
est: 2.27 (-43.7%)
|
-8.93
est: -0.21 (-4,256.1%)
|
2.28
2.26 – 2.30
+1,213.0% YoY
|
2.06
1.87 – 2.26
-9.5% YoY
|
2.36
1.99 – 2.73
+14.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap Value ETF DISV | 0.00% | 97.7K | 0.42% |
| 2 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 52.4K | 0.22% |
| 3 | Avantis Responsible International Equity ETF AVSD | 0.00% | 1.0K | 0.23% |
| 4 | Avantis International Equity ETF AVDE | 0.00% | 4.6K | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jerome Estampes | Group CFO & SVP of Business Development & Licensing | 120.9K | male |
| Philippe Bourrinet | Chief Pharmacist, Deputy Chief Executive Officer, Senior Vice President of Development, Medical & Regulatory Affairs and Deputy MD | 11.5K | male |
| Eric Kummer | Senior VP of Technical Operations | — | — |
| Eva Ohlsson | Senior Vice President of Human Resources & CSR | — | — |
| Francois Nicolas | Chief Digital Officer, SVP of Research, Development, Innovation & AI | — | male |
| François Convenant | SVP of Interventional Radiology and Global VP of Commercial & Interventional Imaging | — | male |
| Karim Boussebaa | Chief Executive Officer | — | male |
| Charlotte Bamiere | General Counsel and SVP of Legal Affairs & Compliance | — | female |
| Valérie Brissart | Senior Vice President of Diagnostic Imaging | — | female |
| Christine Allard | Senior Vice President of Public Affairs & Corporate Communications | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GBT.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
